Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment

被引：0
|
作者：
Sands, Bruce E. [1 ]
Kobayashi, Taku [2 ]
Wu, Jianmin [3 ]
Wang, Isabella Yali [3 ]
Zhu, Baojin [3 ]
Redondo, Isabel [4 ]
Peyrin-Biroulet, Laurent [5 ,6 ]
Walsh, Alissa [7 ]
Magro, Fernando [8 ,9 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] Kitasato Univ, Kitasato Inst Hosp, Minato City, Tokyo, Japan
[3] Eli Lilly & Co, Indianapolis, IN USA
[4] Eli Lilly & Co, Lisbon, Portugal
[5] Nancy Univ Hosp, INFINY Inst, FHU CURE, INSERM,NGERE, Vandoeuvre Les Nancy, France
[6] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[7] Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, England
[8] Univ Porto, Porto, Portugal
[9] Ctr Hosp, Porto, Portugal
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001035164.22459.94
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1449
引用
收藏
页码：S1042 / S1043
页数：2
相关论文
共 50 条
  • [41] Sustained Improvement in Inflammatory Bowel Disease Questionnaire Outcomes in Moderately to Severely Active Ulcerative Colitis With Continued Mirikizumab Treatment in Phase 3 LUCENT-3 Study
    Sands, Bruce E.
    Feagan, Brian G.
    Armuzzi, Alessandro
    McGinnis, Kim
    Lynch, Keisa
    Gibble, Theresa Hunter
    Johns, Jordan
    Siegel, Corey A.
    Jairath, Vipul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S812 - S813
  • [42] Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study
    Feagan, Brian G.
    Matsuoka, Katsuyoshi
    Rogler, Gerhard
    Laharie, David
    Vermeire, Severine
    Danese, Silvio
    Loftus Jr, Edward V.
    Beales, Ian
    Schreiber, Stefan
    Kim, Hyo Jong
    Faes, Margaux
    de Haas, Angela
    Masior, Tomasz
    Rudolph, Christine
    Peyrin-Biroulet, Laurent
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (05) : 563 - 584
  • [43] SUSTAINED IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE OUTCOMES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WITH CONTINUED MIRIKIZUMAB TREATMENT IN PHASE 3 LUCENT-3 STUDY
    Sands, B. E.
    Feagan, B. G.
    Armuzzi, A.
    Mcginnis, K.
    Lynch, K.
    Gibble, Hunter T.
    Johns, J.
    Siegel, C. A.
    Jairath, V.
    Asaro, J.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S166 - S166
  • [44] Cost Per Clinical Outcomes With Biologics for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Jansen, Jeroen P.
    Mody, Reema
    Patel, Haridarshan
    Lorenzi, Maria
    Ursan, Iulia
    Alberton, Mark
    GASTROENTEROLOGY, 2015, 148 (04) : S1 - S2
  • [45] Cost per clinical outcomes with biologics for the treatment of moderately to severely active ulcerative colitis
    Jansen, J.
    Mody, R.
    Ursan, I.
    Lorenzi, M.
    Patel, H.
    Alberton, M.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S239 - S240
  • [46] LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
    Abreu, Maria T.
    Danese, Silvio
    Wolf, Douglas C.
    Canavan, James B.
    Jain, Anjali
    Wu, Hsiuanlin
    Petersen, AnnKatrin
    Charles, Lorna
    Afzali, Anita
    Panaccione, Remo
    GASTROENTEROLOGY, 2023, 164 (06) : S208 - S208
  • [47] Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
    Panaccione, R.
    Danese, S.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Afzali, A.
    Abreu, M. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 534 - 534
  • [48] Early Symptom Control With Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the LUCENT-1 Induction Trial
    Danese, Silvio
    Dignass, Axel
    Matsuoka, Katsuyoshi
    Ferrante, Marc
    Long, Millie
    Redondo, Isabel
    Gibble, Theresa Hunter
    Moses, Richard
    Morris, Nathan
    Li, Xingyuan
    Milch, Catherine
    Abreu, Maria T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S535 - S535
  • [49] Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials
    D'Haens, Geert
    Higgins, Peter D. R.
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Lee, Scott
    Moses, Richard E.
    Redondo, Isabel
    Escobar, Rodrigo
    Gibble, Theresa Hunter
    Keohane, Anthony
    Morris, Nathan
    Zhang, Xin
    Arora, Vipin
    Kobayashi, Taku
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (12) : 2335 - 2346
  • [50] Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extension
    Reinisch, W.
    Gibson, P.
    Sandborn, W. J.
    Feagan, B.
    Marano, C.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Padgett, L.
    Adedokun, O. J.
    Colombel, J. -F.
    Collins, J.
    Rutgeerts, P.
    Tarabar, D.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S248 - S249
12345